Wednesday, June 12, 2013

The display and use of drug information on this site is subject to express terms of use (click here). By continuing to view the drug information, you agree to abide such terms of use.

Rasburicase IV Uses and How to Use


IMPORTANT NOTE: The following information is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that use of the drug is safe, appropriate or effective for you. Consult your healthcare professional before using this drug.

Table of Contents

Generic Name: RASBURICASE - INJECTION
Pronounced: (ras-BURE-i-kase)

Rasburicase IV Uses

This medication is used to prevent high blood levels of uric acid from occurring in children with cancer (e.g., leukemia, lymphoma, solid malignant tumors) who are about to receive cancer chemotherapy treatment. When chemotherapy is given, cancer cells are destroyed, releasing large amounts of uric acid into the bloodstream. This medication allows uric acid to more easily be removed from the body by the kidneys.

How To Use Rasburicase IV

This medication is given by injection into a vein, usually over 30 minutes, or as directed by your doctor. Rasburicase is given once a day for 5 days. Timing of cancer chemotherapy and rasburicase doses is important. Chemotherapy is usually started 4 to 24 hours after the first dose of rasburicase.

Fluids are also given into the vein with this medication to help decrease your uric acid levels.


CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.
Information last revised June 2010 Copyright(c) 2010 First DataBank, Inc.